Skip to content
stock-market — Chronic-diseases — Venture-capital — Health-and-wellness — Investing — Commercial — Mental-health — Eye-health — Cance — Careers — Prescribed — Cholesterol — Medical-conditions — Finance — Housing-market — Digestive-health — Business — Parenting — Entrepreneurship — Aviation — Residential — Automotive — Aging — Aerospace — Cbd — Autoimmune-disorders — Skin-conditions — Nutrition — Skin-care — Public-transit — Ezetimibe — Fintech — Retail — Medicare — Industry — Sexual-health — Mens-health — Fitness-and-exercise — Climate-change — Manufacturing — Space-and-astronomy — Energy — Obcetrapib — Small-business — Science — Womens-health — Weight-management — Workplace-wellness — Transportation — Real-estate — Leadership — Hearing — Lowering

Innovative cholesterol medication reduces LDL levels when conventional statins prove insufficient, research reveals.

A novel drug combination, consisting of a previously authorized substance and a fresh, unapproved one, demonstrates effectiveness in reducing LDL, or harmful cholesterol, when conventional statins prove inadequate.

,   and  Administrator
5 min read

Innovative cholesterol medication reduces LDL levels when conventional statins prove insufficient, research reveals.

Revised Article:

Groundbreaking Combo Drug: Lower Your "Bad" Cholesterol Levels

Get ready to bid adieu to those stubbornly high cholesterol numbers! A new combo pill, combining an already approved medication and a fresh, unapproved one, is making waves. This power duo slashes LDL, the malicious cholesterol, significantly when statins just aren't cutting it.

During a recent Phase 3 trial presented at the European Atherosclerosis Society annual meeting in Glasgow, Scotland, researchers at the Cleveland Clinic revealed that the new pill, with obicetrapib and ezetimibe, decreased LDL cholesterol levels by a whopping 48.6% within three months of use. That's more effective than either drug alone. Ezetimibe, a common cholesterol-lowering medication, is often prescribed alongside statins to further decrease LDL levels.

Dr. Ashish Sarraju, a preventive cardiologist at the Cleveland Clinic, led the study. The multicenter clinical trial enlisted 407 participants, with a median age of 68, who had LDL cholesterol levels over 70 mg/dL despite existing medication to lower it. The subjects were randomly assigned to four groups: a group for the obicetrapib-ezetimibe pill, a group for each drug separately, and a placebo group. All participants continued taking their regular medications while participating in the trial.

As many folks require several prescriptions to get LDL down to their desired levels, the researchers stressed the need to offer patients and their doctors all available options to tackle LDL when facing the threat of cardiovascular disease. High-risk patients have either suffered strokes or heart attacks or are at risk of experiencing them in the future. In light of this, the researchers focused on enrolling participants who, despite already being on statins or even high-intensity statins, still had LDL levels that were too high.

The reduced LDL levels could lead to fewer adverse cardiovascular events such as strokes and heart attacks. According to the American Heart Association, an adult's optimal total cholesterol level is about 150 mg/dL, with LDL levels ideally at or below 100 mg/dL. For high-risk patients, Sarraju suggests an LDL no higher than 70 mg/dL.

The trial was supported by NewAmsterdam Pharma, the manufacturer of obicetrapib. They expect to discuss the new combo drug's approval with the Food and Drug Administration throughout the year.

A host of modifiable factors contribute to elevated LDL levels, including a diet high in saturated fats, processed foods, and fried foods; being overweight; smoking; and aging.

Dr. Robert Rosenson, director of lipids and metabolism for the Mount Sinai Health System in New York City, expressed cautious optimism. Other drugs in the same class have failed to reduce heart attacks or stroke, but he's keeping a hopeful eye on obicetrapib. The drugmaker is running a follow-up trial to determine if the combo pill not only reduces cholesterol levels but also shields against adverse heart events.

While lifestyle changes can play a role in cholesterol management, levels remain seemingly impervious for some individuals. Only 20% of high-risk heart disease patients can effectively manage their LDL levels, according to Dr. Corey Bradley, a cardiologist at the Columbia University Vagelos College of Physicians and Surgeons. Heart disease is the leading cause of death for adults in the United States.

"High LDL is one of the leading risk factors for heart disease, but we struggle to control that risk," Bradley pointed out. "Many people have such high LDL they will require multiple medications to control it."

Bradley is enthusiastic about innovative drugs like obicetrapib.

Suggested Articles:

Trump Administration Halts CDC's Infection Control Committee

Measles Outbreak Slows in West Texas, Doctors Remain Alert

Recommendation:

Health Updates

Stay informed about the latest advancements in health and wellness with our diverse collection of articles. Don't miss out on the latest research and updates that could significantly impact your health journey. Visit us daily for new insights and expert advice!

  1. The new combo pill, combining obicetrapib and ezetimibe, is poised to revolutionize healthcare, specifically in managing cholesterol levels.
  2. The combo drug significantly reduces LDL cholesterol levels by a remarkable 48.6%, making it more effective than either drug alone.
  3. Traditionally, ezetimibe is prescribed alongside statins to further decrease LDL levels, but this duo offers a potential alternative for those not responding to statins.
  4. In a recent Phase 3 trial, researchers at the Cleveland Clinic demonstrated the efficacy of this combo pill, enlisting 407 participants with a median age of 68.
  5. For high-risk patients, this reduced LDL could lead to fewer adverse cardiovascular events such as strokes and heart attacks.
  6. As many patients require multiple prescriptions to manage their LDL levels, the researchers emphasized the need to offer patients and their doctors all available options.
  7. The American Heart Association recommends an adult's optimal total cholesterol level at about 150 mg/dL, with LDL levels ideally at or below 100 mg/dL.
  8. For high-risk patients, Sarraju suggests an LDL no higher than 70 mg/dL.
  9. The trial was supported by NewAmsterdam Pharma, the manufacturer of obicetrapib, and they expect to discuss the new combo drug's approval with the Food and Drug Administration throughout the year.
  10. Factors contributing to elevated LDL levels include a diet high in saturated fats, processed foods, and fried foods; being overweight; smoking; and aging.
  11. Dr. Robert Rosenson, director of lipids and metabolism for the Mount Sinai Health System in New York City, expressed cautious optimism about the new drug.
  12. Other drugs in the same class have failed to reduce heart attacks or stroke, but Rosenson stays hopeful about obicetrapib.
  13. The drugmaker is running a follow-up trial to determine if the combo pill not only reduces cholesterol levels but also shields against adverse heart events.
  14. Lifestyle changes play a role in cholesterol management, but levels remain challenging for some individuals.
  15. Only 20% of high-risk heart disease patients can effectively manage their LDL levels, according to Dr. Corey Bradley, a cardiologist at the Columbia University Vagelos College of Physicians and Surgeons.
  16. Heart disease is the leading cause of death for adults in the United States.
  17. High LDL is one of the leading risk factors for heart disease, but we struggle to control that risk.
  18. Many people have such high LDL they will require multiple medications to control it.
  19. Bradley is enthusiastic about innovative drugs like obicetrapib.
  20. In the workplace-wellness sector, offering comprehensive healthcare solutions, including cholesterol-lowering therapies, can increase employee productivity and mental health.
  21. As a result, companies are investing in workplace-wellness programs, addressing medical conditions, chronic diseases, cancer, respiratory conditions, digestive health, eye health, hearing, and other health-and-wellness aspects.
  22. Fitness-and-exercise programs, mental-health initiatives, and workforce training in diversity-and-inclusion are additional components of these comprehensive wellness strategies.
  23. Furthermore, men's health, sexual-health, and autoimmune-disorders management are becoming essential topics in the health-and-wellness discussion.
  24. Climate-change awareness and sustainability initiatives are also gaining importance in the health-and-industry.
  25. Manufacturing firms are focusing on reducing greenhouse gas emissions and implementing energy-efficient solutions to minimize their environmental impact.
  26. The manufacturing sector's shift towards promoting green technologies contributes to the environmental-science field while creating new opportunities in the energy market.
  27. Alongside health, the finance industry plays a crucial role in managing healthcare costs, advocating for mental-health awareness, and encouraging investing in clean energy.
  28. Entrepreneurship opportunities are emerging in innovative therapies-and-treatments, nutrition, skin-care, and aging solutions, as well as in eco-friendly retail and public-transit options.
  29. Advances in neurological-disorders research and ventures in aerospace, transportation, leadership, and small-business development also influence health-related trends.
  30. With the advent of digital technologies such as fintech, artificial intelligence, and blockchain, the future of healthcare and health-related businesses is evolving rapidly, leading to improved care, early disease detection, and personalized treatments.
Unapproved drug blend lowers
Emerging combination drug reduces excess

Read also:

    Related

    Latest